ClinicalTrials.gg
CompletedNCT07951346Updated Nov 20, 2026

N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Hospitalized Tuberculosis Patients

A Phase 2 interventional study of N-acetylcysteine (NAC) in Drug-Induced Liver Injury and Tuberculosis, sponsored by RSUP Persahabatan. Completed at 1 site in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by RSUP Persahabatan · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2026, registered Nov 2026).
Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Anti-tuberculosis drug-induced liver injury (AT-DILI) is a common side effect of tuberculosis (TB) treatment. It often forces TB drugs to be stopped temporarily, which may reduce treatment success. N-acetylcysteine (NAC) is an antioxidant that helps the body make glutathione and may help the liver recover. Most previous studies tested NAC to prevent liver injury rather than to treat liver injury that has already occurred.

This study aimed to find out whether oral NAC, given as an adjuvant therapy, improves liver function and nausea-vomiting in hospitalized adults with drug-susceptible TB who developed AT-DILI. Participants were randomly assigned to receive effervescent NAC 600 mg twice daily for 7 days or no NAC. Liver tests (ALT, AST, and total bilirubin) were measured on days 0, 3, 6, and 9, and nausea and vomiting were assessed daily from day 0 to day 9.

Read the detailed description

Design: open-label, randomized, parallel-group clinical trial at Persahabatan National Respiratory Referral Hospital, Jakarta, Indonesia, from February to September 2026.

AT-DILI definition: ALT/AST ≥3 times the upper limit of normal (ULN) with symptoms, and/or ≥5 times ULN without symptoms, and/or total bilirubin >2 mg/dL.

Procedures: Patients were screened using baseline laboratory results at hospital admission (day 0). After confirmation of TB diagnosis, AT-DILI, eligibility criteria, and written informed consent, baseline ALT, AST, total bilirubin, and clinical characteristics were recorded. Participants were then randomized to (A) effervescent NAC 600 mg twice daily or (B) no NAC. The intervention was given for 7 days. Participants were hospitalized for at least 6 days and had a follow-up visit on day 9. ALT, AST, and total bilirubin were measured on days 3, 6, and 9 (day 9 tests were done at the outpatient visit or during hospitalization). Nausea and vomiting severity was assessed daily from day 0 to day 9 using the Rhodes Index of Nausea, Vomiting, and Retching (RINVR); for participants discharged by day 6, days 7 and 8 were assessed at the day 9 visit.

Sample size: minimum 21 participants per group (two-sided alpha 0.05, power 80%, SD 40 U/L, minimal clinically meaningful difference 35 U/L), using total sampling during the study period.

Statistical analysis: normality tested with Shapiro-Wilk. Changes in ALT, AST, and total bilirubin at days 3, 6, and 9 were compared between groups using the unpaired t-test or Mann-Whitney test. Daily nausea-vomiting severity was analyzed with generalized estimating equations (GEE) with a cumulative logit link. Potential confounders: age, sex, nutritional status (BMI), and type 2 diabetes mellitus. Analyses were performed with SPSS version 26.0.

02

Conditions studied

  • Drug-Induced Liver Injury
  • Tuberculosis

Keywords

  • N-acetylcysteine
  • Anti-tuberculosis drug-induced liver injury
  • Adjuvant therapy
  • Transaminases
  • Hepatotoxicity
03

In context

Chemical and Drug Induced Liver Injury

81 studies on the registry are indexed under Chemical and Drug Induced Liver Injury; 21 are open to participants now.

This study's enrollment of 28 is below the median of 80 across 40 interventional studies indexed under Chemical and Drug Induced Liver Injury.

Browse Chemical and Drug Induced Liver Injury studies →

Lead sponsor

RSUP Persahabatan is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Active drug-susceptible tuberculosis (pulmonary or extrapulmonary) currently receiving anti-tuberculosis drugs.
  • Drug-induced hepatitis meeting at least one of the following: /AST ≥3 times the with symptoms; ALT/AST ≥5 times the upper limit of normal without symptoms; total >2 mg/dL.
  • Willing to participate and signed .

Exclusion criteria

Exclusion Criteria:

  • History of chronic liver disease ( or C, cirrhosis).
  • Chronic kidney failure, disease, or other severe systemic conditions.
  • Current alcohol consumption.
  • Pregnancy or breastfeeding.
  • to or history of allergy to N-acetylcysteine.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    N-Acetylcysteine (NAC)

    Participants received effervescent N-acetylcysteine 600 mg orally twice daily for 7 days.

    Drug: N-acetylcysteine (NAC)

  • No intervention
    No NAC (Control)

    Participants did not receive N-acetylcysteine.

Interventions

  • DrugAcetylcysteineStudies of AcetylcysteineAcetylcysteine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Effervescent N-acetylcysteine 600 mg tablet, taken orally twice daily (2 × 600 mg) for 7 days.

    Also known as: Acetylcysteine, NAC

06

What researchers measure

Primary outcomes

  1. Change in Serum Alanine Aminotransferase (ALT/SGPT)

    Change in serum ALT (U/L) from baseline (day 0) to day 3, day 6, and day 9, compared between the NAC and no-NAC groups.

    Time frame: Baseline (day 0), day 3, day 6, and day 9

  2. Change in Serum Aspartate Aminotransferase (AST/SGOT)

    Change in serum AST (U/L) from baseline (day 0) to day 3, day 6, and day 9, compared between the NAC and no-NAC groups.

    Time frame: Baseline (day 0), day 3, day 6, and day 9

Secondary outcomes

  1. Change in Serum Total Bilirubin

    Change in serum total bilirubin (mg/dL) from baseline (day 0) to day 3, day 6, and day 9, compared between the NAC and no-NAC groups.

    Time frame: Baseline (day 0), day 3, day 6, and day 9

  2. Severity of Nausea and Vomiting

    Daily severity of nausea and vomiting assessed with the Rhodes Index of Nausea, Vomiting, and Retching (RINVR), categorized as normal, mild, moderate, severe, or very severe.

    Time frame: Daily from day 0 to day 9

07

Study locations

1 site
  • Persahabatan National Respiratory Referral Hospital
    Jakarta, DKI Jakarta 13230, Indonesia
08

References and documents

Publications

  • Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR; ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52. doi: 10.1164/rccm.200510-1666ST. PubMed 17021358 ↗
  • Mapamba DA, Sauli E, Mrema L, Lalashowi J, Magombola D, Buza J, Olomi W, Wallis RS, Ntinginya NE. Impact of N-Acetyl Cysteine (NAC) on Tuberculosis (TB) Patients-A Systematic Review. Antioxidants (Basel). 2022 Nov 21;11(11):2298. doi: 10.3390/antiox11112298. PubMed 36421484 ↗
  • Sanabria-Cabrera J, Tabbai S, Niu H, Alvarez-Alvarez I, Licata A, Bjornsson E, Andrade RJ, Lucena MI. N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. Front Pharmacol. 2022 May 17;13:876868. doi: 10.3389/fphar.2022.876868. eCollection 2022. PubMed 35656297 ↗
  • Sukumaran D, Usharani P, Paramjyothi GK, Subbalaxmi MVS, Sireesha K, Abid Ali M. A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. Indian J Tuberc. 2023 Jul;70(3):303-310. doi: 10.1016/j.ijtb.2022.05.012. Epub 2022 Jun 1. PubMed 37562904 ↗
  • Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR, Velayati AA. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol. 2010 Oct;22(10):1235-8. doi: 10.1097/MEG.0b013e32833aa11b. PubMed 20461008 ↗
  • Moosa MS, Maartens G, Gunter H, Allie S, Chughlay MF, Setshedi M, Wasserman S, Stead DF, Hickman N, Stewart A, Sonderup M, Spearman CW, Cohen K. A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. Clin Infect Dis. 2021 Nov 2;73(9):e3377-e3383. doi: 10.1093/cid/ciaa1255. PubMed 32845997 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared publicly. The study was a small, single-center rial, and participants consented to the use of their data for this study only. Data contain clinical information from hospitalized patients and are kept confidential in accordance with the approval of the Health Research Ethics Committee, Persahabatan Hospital. Aggregate results will be reported in the thesis and in a peer-reviewed publication.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Sep 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartActual
Feb 1, 2026
Primary completionActual
Sep 14, 2026
CompletionActual
Sep 30, 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951346
Lead sponsor
RSUP Persahabatan
Collaborators
Universitas Indonesia
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Feb 1, 2026
Primary completion
Sep 14, 2026
Completion
Sep 30, 2026
Last update
Nov 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcysteine

Start the discussion